Summary
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive.
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Haemonetics Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 159 | $12,732.92 | $12,600.75 | -$132.17 | -1.04% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 172 | $8,383.28 | $13,584.56 | $5,201.28 | 62.04% |
| BG Bart Gancher Intech Investment Management LLC | 32,926 | $2.26M | $2.6M | $343,008.6 | 15.18% |
 Bridgewater Associates LP Bridgewater Associates LP | 48,377 | $2.73M | $3.82M | $1.1M | 40.22% |
 Point72 Asset Management LP Point72 Asset Management LP | 56,868 | $4.56M | $4.49M | -$63,692.17 | -1.4% |
Haemonetics Corporation (HAE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Haemonetics Corporation ever had a stock split?
Haemonetics Corporation Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Christopher A. Simon CEO | NYSE Exchange | 405024100 CUSIP |
| US Country | 3,009 Employees | - Last Dividend | 3 Dec 2012 Last Split | 9 May 1991 IPO Date |
Overview
Haemonetics Corporation is a leading healthcare provider that specializes in developing a comprehensive suite of medical products and solutions. With a global presence, the company is dedicated to enhancing the efficiency and safety of blood and plasma collection, processing, and management. Founded in 1971 and headquartered in Boston, Massachusetts, Haemonetics Corporation has been at the forefront of innovation, offering advanced technologies to support hospitals, blood banks, and plasma collection centers in improving patient care and outcomes.
Products and Services
- Automated Plasma Collection Systems and Software Solutions:
Includes NexSys PCS and PCS2 plasmapheresis equipment, related disposables, and intravenous solutions. Offers integrated IT platforms like NexLynk DMS donor management system and Donor360, designed for plasma customers to streamline donor management, operations, and supply chain management.
- Automated Blood Component and Manual Whole Blood Collection Systems:
Features the MCS brand apheresis equipment, which enables the collection of specific blood components from donors. Also provides disposable collection and component storage sets, SafeTrace Tx blood bank information system, and BloodTrack management software, facilitating efficient blood management and transfusion processes.
- Hospital Products:
Offers TEG, ClotPro, and HAS hemostasis analyzer systems for a comprehensive assessment of a patient's hemostasis. TEG Manager software connects TEG analyzers across the hospital, allowing clinicians remote access to test results to inform treatment decisions. Cell Saver Elite +, an autologous blood recovery system, is suited for various surgeries, enhancing recovery and minimizing transfusion needs.
- VASCADE Products:
Including VASCADE and VASCADE MVP, this technology platform leverages the natural clotting mechanism with a catheter-based delivery system for vascular closure, designed to improve patient outcomes and reduce recovery time after procedures.
